Search - tctmd.com

Displaying 821 - 840 of 2239

Sort: Relevancy | Date

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

News Daily News

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

October 15, 2019

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

News Daily News

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

October 15, 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

October 09, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

Interventional Options and Future Directions for Acute PE: New AHA Statement

News Daily News

Interventional Options and Future Directions for Acute PE: New AHA Statement

October 07, 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

October 04, 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

October 03, 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presentation TCT 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presenter: Renu Virmani

September 28, 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

September 28, 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

September 28, 2019

SCOPE I: Acurate Neo Comes Up Short for Severe Aortic Stenosis

News Conference News TCT 2019

SCOPE I: Acurate Neo Comes Up Short for Severe Aortic Stenosis

Marcus A. Banks

September 27, 2019

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Presentation TCT 2019

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Presenter: Eric Secemsky

September 27, 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

September 26, 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.